Ironwood Pharmaceuticals Forecast, price target & analysts
Ironwood Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Ironwood Pharmaceuticals Classifications & Recommendation
Ironwood Pharmaceuticals Price Target
| Target Price | $5.46 |
| Price | $4.23 |
| Potential |
29.01%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Ironwood Pharmaceuticals 2027 .
The average Ironwood Pharmaceuticals target price is $5.46.
This is
29.01%
register free of charge
$10.50
148.23%
register free of charge
$3.74
11.65%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Ironwood Pharmaceuticals to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ironwood Pharmaceuticals stock has an average upside potential 2027 of
29.01%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 296.15 | 481.03 |
| 15.73% | 62.43% | |
| EBITDA Margin | 40.74% | 70.90% |
| 46.48% | 74.05% | |
| Net Margin | 8.11% | 42.98% |
| 3,138.86% | 429.91% |
6 Analysts have issued a sales forecast Ironwood Pharmaceuticals 2026 . The average Ironwood Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Ironwood Pharmaceuticals EBITDA forecast 2026. The average Ironwood Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Ironwood Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Ironwood Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.15 | 1.25 |
| 1,400.00% | 733.33% | |
| P/E | 3.38 | |
| EV/Sales | 2.09 |
6 Analysts have issued a Ironwood Pharmaceuticals forecast for earnings per share. The average Ironwood Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Ironwood Pharmaceuticals...
Current Ironwood Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citizens |
Locked
➜
Locked
|
Locked | Feb 26 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Jan 05 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jan 05 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Apr 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citizens:
Locked
➜
Locked
|
Feb 26 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Jan 05 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jan 05 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Apr 15 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Apr 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
